Related Experiment Video

Updated: May 14, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Alzheimer disease biomarkers and insights into mild cognitive impairment

David S Knopman1

  • 1Alzheimer's Disease Research Center and Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. knopman@mayo.edu

Neurology
|February 8, 2013
PubMed

Insights

Mild cognitive impairment (MCI) presents variable prognoses, with some individuals progressing to dementia and others improving. Identifying those at highest risk is crucial for effective research and clinical care.

Area of Science:

  • Neurology
  • Gerontology
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) is characterized by noticeable changes in thinking and memory, yet individuals remain largely independent in daily activities.
  • MCI patients exhibit a significantly higher risk of progressing to dementia compared to cognitively normal individuals, though prognosis varies at the individual level.
  • Some individuals with MCI may not experience worsening of symptoms, and a subset may even revert to cognitive normality.

Discussion:

  • The inherent uncertainty in MCI prognosis contributes to its clinical recognition and the term's widespread adoption.
  • Accurately predicting which MCI patients are most likely to develop severe cognitive impairment is a critical research objective.
  • While traditional assessments like history, mental status tests, and neuropsychological evaluations are informative, they still leave uncertainty in predicting disease progression.

Key Insights:

  • Mild cognitive impairment (MCI) is a transitional stage with unpredictable outcomes, ranging from stability to dementia progression or even recovery.
  • Identifying individuals with MCI who are at high risk for dementia is a significant challenge in clinical practice and research.
  • Current diagnostic methods for MCI provide a baseline but are insufficient for precise prognostic predictions.

Outlook:

  • Future research should focus on developing more accurate biomarkers and predictive models to identify MCI patients at high risk of dementia.
  • Improved prognostic tools will enable personalized interventions and more effective management strategies for individuals with MCI.
  • Understanding the factors influencing MCI progression is essential for developing targeted therapies to prevent or delay dementia onset.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...